吉西他滨单药与多西他赛单药治疗老年晚期非小细胞肺癌的临床研究

Clinical research of gemcitabine single-agent and docetaxel single-agent in treatment of elderly advanced non-small cell lung cancer

目的观察吉西他滨单药与多西他赛单药一线治疗老年晚期非小细胞肺癌的疗效及不良反应。方法分析55例老年晚期非小细胞肺癌患者,吉西他滨单药化疗29例,多西他赛单药化疗26例,评价疗效及不良反应。结果 55例无CR病例,吉西他滨组PR 8例,SD 11例,PD 10例,中位生存期为5.5个月;多西他赛组PR 7例,SD 12例,PD 7例,中位生存期为6个月。两组比较RR及中位生存期差异无统计学意义(P>0.05)。多西他赛组中性粒细胞减少及消化道黏膜反应的发生率略高于吉西他滨组。结论吉西他滨单药与多西他赛单药治疗老年晚期非小细胞肺癌疗效相当,但吉西他滨不良反应的发生率低。

Objective To observe curative effect and adverse reactions of the gemcitabine single-agent and docetaxel single-agent in treatment of elderly advanced non-small cell lung cancer. Methods The clinic data of 55 cases of elderly patients with advanced non-small cell lung cancer were ardyzed, including 29 cases with gemcitabine single-agent chemotherapy and the rest 26 cases with docetaxel single-agent chemotherapy. The curative effect and adverse reactions were evaluated. Results There were no cases with CR in 55 cases. In the gemcitabine group therein, there was 8 casesof PR, 11 cases of SD, 10 cases of PD, and the median survival was 3.5 months. In the docetaxel group, there was 7 cases of PR, 12 cases of SD, 7 cases of PD, and the median survival period was 6 months. There was no statistical significance in RR and the median survival （ P 〉 0. 05 ） between the two groups were compared. The incidence of neutropenia and digestive tract mucosa reaction of docetaxel group were higher than gemcitabine group. Conclusion The efficacy of gemeitabine single-agent and docetaxel monotherapy in the treatment of elderly advanced non-small cell lung cancer are similar, but gemcitabine has low incidence of adverse reactions.